CTI BioPharma Corp. (CTIC)

Oncology Corporate Profile

Stock Performance

4.3700
0.0000

HQ Location

3101 Western Avenue
Seattle, WA 98121

Company Description

CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers. We see patients as people, looking at potential therapies from the patient’s perspective to address both the clinical need and the impact treatment can have on a patient’s life. We prioritize the patient experience and are committed to developing therapeutic options for people living with cancer who want a chance at a longer and better quality of life.

Website: http://www.ctibiopharma.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Opaxio_ / paclitaxel poliglumex / CT-2103microtubule inhibitorNon Small Cell Lung Cancer (NSCLC)III
Opaxio_ / paclitaxel poliglumex / CT-2103microtubule inhibitorOvarian cancerIII
Pixuvri_ / pixantrone / BBR 2778anthracyclineDiffuse large B-cell Lymphoma (DLBCL)III
Pixuvri_ (+ Rituxan_) / pixantrone (+ rituximab) / BBR 2778anthracycline2nd line metastatic B-cell Non-Hodgkin's Lymphoma (NHL)III
tosedostatAADR inducer2nd line metastatic Acute Myelogenous Leukemia (AML)II
tosedostatAADR inducerMyelodysplastic Syndrome (MDS)II
brostallicinDNA minor groove binding agent (synthetic)Soft tissue sarcomaII
Opaxio_ / paclitaxel poliglumex / CT-2103microtubule inhibitorEsophageal cancerII
Opaxio_ / paclitaxel poliglumex / CT-2103microtubule inhibitorGlioblastoma Multiforme (GBM)II
Pixuvri_ / pixantrone / BBR 2778anthracycline1st line metastatic Breast cancer (HER2-)II
Pixuvri_ / pixantrone / BBR 2778anthracycline1st line metastatic Non-Hodgkin's Lymphoma (NHL)II
Pixuvri_ / pixantrone / BBR 2778anthracycline2nd line metastatic indolent LymphomaII
Pixuvri_ / pixantrone / BBR 2778anthracycline2nd line metastatic Non-Hodgkin's Lymphoma (NHL)II
CT-3610dinuclear-platinum complexVarious cancer typesPreclinical
UnnamedHIF-1 inhibitorVarious cancer typesResearch

View additional information on product candidates here »

Source


http://www.ctibiopharma.com

Recent News Headlines

McKesson Specialty Health Hosts 2016 Onmark Fall Leadership Summit For Community-Based Oncology Practices

11/7/2016 11:29 am

(McKesson) Nov 7, 2016 - Attendees gained valuable insight into preparing their practices for value-based care.

Breast Cancer Patients Have New Surgery Option with Radioactive Seed

11/4/2016 10:45 am

(UC Davis CCC) Nov 3, 2016 - UC Davis Comprehensive Cancer Center now offers a new technique for breast cancer patients undergoing surgery to remove breast cancer that may improve cosmetic outcomes and the patient’s surgery experience.

ASCO Launches COME HOME Initiative to Give Oncology Practices Concrete Path toward Alternative Payment System

11/2/2016 11:28 am

(ASCO) Nov 1, 2016 - The American Society of Clinical Oncology (ASCO) and Innovative Oncology Business Solutions, Inc., (IOBS) today announced a new collaboration, ASCO COME HOME, an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer.

MD Anderson-Led Study Develops Prediction Model For Lung Cancer Risk In Never Smokers

11/2/2016 11:10 am

(MD Anderson) Nov 2, 2016 - Researchers at The University of Texas MD Anderson Cancer Center have developed a new personalized assessment tool that could better predict lung cancer risk in never, light and heavy smokers using a large Taiwanese prospective cohort study.

CMS Finalizes Hospital Outpatient Prospective Payment System Changes to Better Support Hospitals and Physicians and Improve Patient Care

11/2/2016 07:06 am

(CMS.gov) Nov 1, 2016 - Today, the Centers for Medicare & Medicaid Services (CMS) finalized updated payment rates and policy changes in the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System for calendar year (CY) 2017.

Merrimack Announces Acceptance for Review of ANDA filed by Actavis for Generic Doxorubicin Hydrochloride Liposome Injection (aka DOXIL(R))

10/31/2016 10:37 am

(The Business Journal) Oct 31, 2016 - Merrimack Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for generic doxorubicin hydrochloride (HCI) liposome injection submitted by its partner Actives LLC.

October 31: CVS/Caremark Notifies Practices of Network Reversal Decision

10/31/2016 10:30 am

(COA) Oct 31, 2016 - Late Friday, community oncology practices that dispense medications to their patients received notification via fax that CVS/Caremark had reversed its decision to force them as out-of-network providers.

Breast Reconstruction Worthwhile for Older Women: Study

10/31/2016 10:25 am

(U.S. News & World Report/HealthDay News) Oct 28, 2016 - Older women who have had a breast removed due to cancer benefit as much as younger women from breast reconstruction, a new study shows.

Adaptive Biotechnologies Announces the Inclusion of NGS-Based MRD Assessment in the NCCN Clinical Practice Guidelines for Multiple Myeloma

10/28/2016 12:19 pm

(Yahoo! Finance) Oct 27, 2016 - Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces that the National Comprehensive Cancer Network (NCCN) revised their clinical practice guidelines recommending the use of highly sensitive diagnostic tools, including NGS, to assess the presence of measurable residual disease (MRD) in Multiple Myeloma.

Clinical and Patient-Reported Outcomes Are the Same for Older and Younger Women Who Have Breast Reconstruction after Mastectomy for Breast Cancer

10/27/2016 11:42 am

(American College of Surgeons) Oct 26, 2016 - The most comprehensive study of its kind to date found that older women enjoy the same benefits from breast reconstruction following mastectomy for breast cancer as younger women without a significant increase in the risk for complications.

How Can Practices Seek Success With Oncology Payment Reform?

10/26/2016 11:48 am

(AJMC) Oct 25, 2016 - At the Payer Exchange Summit V, sponsored by the Community Oncology Alliance (COA), held October 24-25, 2016, in Tyson’s Corner, Virginia, Bruce Gould, MD, medical director, Northwest Georgia Oncology Center, presented an overview of how cancer care has improved over the years, what the challenges are, and how practices can adapt to payment reform.

Access 2015 PQRS and QRUR Reports to Determine 2017 Payment Adjustments for Your Practice

10/26/2016 11:47 am

(ASCO in Action) Oct 25, 2016 - In late September, the Centers for Medicare and Medicaid Services (CMS) released the 2015 Physician Quality Reporting System (PQRS) Feedback Reports and 2015 Annual Quality and Resource Use Reports (QRURs). These reports are used to determine whether a practice will receive bonuses or be subject to PQRS and Value Modifier payment penalties in 2017.

Cancer Risk Reduction in the Trenches: PCPs Respond

10/25/2016 12:29 pm

(Medscape Medical News) Oct 25, 2016 - Cancer is often cited as the disease most Americans fear, and the latest statistics from the National Cancer Institute show that it will affect more than 1 in 3 people (39%).

Preclinical Research Demonstrates Peregrine Pharmaceuticals' PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC)

10/24/2016 11:51 am

(Peregrine Pharmaceuticals) Oct 24, 2016 - Peregrine Pharmaceuticals, Inc., a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced the presentation of preclinical study data demonstrating that phosphatidylserine (PS)-targeting antibodies similar to bavituximab are able to enhance the anti-tumor activity of anti-PD-L1 therapy in a model of triple negative breast cancer (TNBC).

A Novel Non-Invasive Imaging Probe for Fast and Sensitive Detection of Cancer

10/24/2016 11:49 am

(Toyko Tech [Japan]) Oct 21, 2016 - The ultimate goal of cancer diagnostics is to develop sensitive imaging techniques for reliable detection of tumor malignancy in the body. Scientists at Tokyo Institute of Technology have come close to achieving this goal by developing an injectable imaging probe that can specifically detect solid tumors based on the activity of hypoxia-inducible factor (HIF) regulated by the ubiquitin-proteasome system.

Federal Prosecutors Accuse Local Medical Practice of Fraud

10/21/2016 12:17 pm

(Poughkeepsie Journal [New York]) Oct 21, 2016 - A local medical group that treats patients with cancer and blood disorders took illegal kickbacks and filed false Medicare claims, according to a complaint filed by federal prosecutors.

Connecting the Moonshot to Patients

10/21/2016 12:16 pm

(ACCCBuzz) Oct 21, 2016 - The Cancer Moonshot framed Thursday’s sessions at the ACCC 33rd National Oncology Conference in St. Louis. “I’ve been privileged to be part of the conversations around the Moonshot,” ACCC President Jennie R. Crews, MD, MMM, FACP, told attendees in her opening remarks.

Some Websites May Not be Effective in Helping Pancreatic Cancer Patients Make Optimal Treatment Decisions

10/19/2016 11:34 am

(American College Of Surgeons) Oct 18, 2016 - Cancer patients often turn to the Internet to find information about treatment options, but not all websites are created equal. Websites featuring pancreatic treatment modalities differ significantly in the way they present information based on therapy type, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.

Contralateral Prophylactic Mastectomy is a Popular Treatment Choice among Breast Cancer Patients in an Online Health Community

10/19/2016 11:33 am

(American College Of Surgeons) Oct 18, 2016 - Fearing recurrence, patients opted for an aggressive double mastectomy despite evidence that a lumpectomy or single mastectomy would also be effective.

Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients, Met Primary Endpoint

10/19/2016 11:16 am

(Yahoo! Finance) Oct 19, 2016 - Merck & Co., Inc., known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary endpoint.

Investigational Immunotherapy Was Safe, Tolerable, and Showed Some Activity Against Melanoma

10/19/2016 11:15 am

(AACR) Oct 19, 2016 - The investigational immunotherapeutic IMC-20D7S was safe, well tolerated, and showed signs of modest clinical activity for patients with advanced melanoma, according to results from a first-in-human phase I clinical trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Check-Cap Announces Presentation of Clinical Data Demonstrating Safety and Detection of Polyps Using Preparation-Free Colorectal Cancer Screening Capsule

10/18/2016 11:35 am

(The Business Journals) Oct 18, 2016 - Data presented at the American College of Gastroenterology Annual Scientific Meeting and the United European Gastroenterology Week.

A Cancer Patient And Pathologist — Brought Together By Twitter — Strike Up An Unlikely Connection

10/17/2016 11:32 am

(STAT/First Opinion) Oct 17, 2016 - We believe that closer, more personal connections between physicians, including pathologists, and their patients can create a better understanding of cancer, from both scientific and humanistic perspectives.

FACT SHEET: Vice President Biden Delivers Cancer Moonshot Report, Announces Public and Private Sector Actions to Advance Cancer Moonshot Goals

10/17/2016 11:11 am

(WhiteHouse.gov/Office of the Vice President) Oct 17, 2016 - Today in the Oval Office, Vice President Joe Biden delivered the Cancer Moonshot report to the President and the American public.

Practice-Changing Potential for Breast Cancer

10/15/2016 12:00 am

What jumped out this year at ASCO and ESMO for physicians treating breast cancer? How did these two major meetings change the course of breast cancer treatment in 2016? We look at six trials presented at the meetings with that kind of potential.

CDC Endorses A More Effective HPV Vaccine To Prevent Cancer

2/2/2016 12:00 pm

(NPR/Shots blog) Feb 1, 2016 - The updated childhood immunization schedule, released today from the Centers for Disease Control and Prevention, includes a couple tweaks to vaccine recommendations for older children and teens.

Genetic Chaos In Tumours Could Help Predict Chemo Response

8/4/2015 11:02 am

(Cancer Research UK) Aug 4, 2015 - Francis Crick Institute and UCL Cancer Institute scientists, funded by Cancer Research UK, the Academy of Medical Sciences and the National Institute for Health Research, have shown how the level of genetic chaos in tumours could help predict patients’ response to chemotherapy according to research published in Cancer Discovery.

Potential New Therapy Approaches To Reverse Kidney Damage Identified

8/4/2015 11:02 am

(MD Anderson) Aug 3, 2015 - Study shows that cell plasticity program resulting from kidney damage can be targeted to reverse disease and fibrosis.

MD Anderson Study Reveals New Insight Into DNA Repair

8/4/2015 11:02 am

(MD Anderson) Aug 3, 2015 - DNA double-strand breaks (DSBs) are the worst possible form of genetic malfunction that can cause cancer and resistance to therapy.

New Cancer Plan Could Save Thousands

7/20/2015 11:04 am

(PharmaTimes [UK]) July 20, 2015 - An Independent Cancer Taskforce has outlined six priority areas to help the National Health Service improve cancer outcomes in England in a new strategy, which could save and extend thousands of lives.

Living With Cancer: Curses and Blessings

7/17/2015 11:03 am

(New York Times/Well blog) July 16, 2015 - Like someone with bipolar disorder, I see-saw between irritability and elation, depression and euphoria.

Simple Test May Help Predict the Need for Repeat Colonoscopy

7/7/2015 11:05 am

(Medscape Medical News) July 6, 2015 - A simple panel of genetic biomarkers may be able to predict which individuals are at high and low risk of developing colorectal cancer following screening colonoscopy, and therefore could identify those who should have repeat screening, say a team of researchers from Luxembourg.

Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

6/11/2015 11:05 am

(MarketWatch) June 10, 2015 - Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-120 for treatment of patients with acute myelogenous leukemia (AML).

Women Four Times Less Likely to Have Surgery if Breast Cancer Diagnosed as an Emergency

6/8/2015 11:04 am

(Cancer Research UK) June 8, 2015 - Breast cancer patients are four times less likely to have potentially lifesaving surgery if diagnosed as an emergency rather than through an urgent GP referral, according to new data* published today (Monday).

Downsizing After Phase III Bust

6/3/2015 11:03 am

(European Biotechnology) June 2, 2015 - After disappointing Phase III results for immunotherapy tasquinimod and the subsequent discontinuation of the prostrate cancer drug, Swedish Active Biotech is now severely downsizing its operations.

Merck Extends Immuno-Oncology Collaboration with Agenus

6/3/2015 11:03 am

(MarketWatch) June 3, 2015 - Collaboration involves two proprietary Merck targets.

Perspective: Screening for Lung Cancer with Low-Dose CT — Translating Science into Medicare Coverage Policy

5/29/2015 03:00 pm

(NEJM) May 28, 2015 - Although low-dose computed tomography (CT) has been studied in several screening trials, the National Lung Screening Trial (NLST), sponsored by the National Cancer Institute, is the only trial to date that has shown that screening with low-dose CT reduces lung-cancer mortality.

Billionaire David Koch Pledges Record $150 Million For New Cancer Center

5/21/2015 12:03 pm

(Forbes) May 20, 2015 - David Koch, the 7th richest man in the world with a net worth of $42.7 billion, has pledged $150 million to Memorial Sloan Kettering to build a new outpatient cancer facility on Manhattan’s Upper East Side, the world-renowned cancer center announced Wednesday.

Puma Biotechnology Founder Auerbach Loses $250 Million on Cancer Drug Data

5/14/2015 01:05 pm

(Forbes) May 13, 2015 - On Wednesday afternoon, Forbes estimated Puma Biotechnology Founder, Chairman, and Chief Executive Alan Auerbach’s net worth at $1.19 billion.

Obamacare Program Generates 'Substantial' Medicare Savings

5/4/2015 11:02 am

(CNBC) May 4, 2015 - An Obamacare program designed to hold down Medicare costs and improve patient outcomes has generated more than $384 million in savings in its first two years of operation, Health and Human Services Secretary Sylvia Burwell said Monday.

Fast/Slow Telomere Shortening Predicts Cancer

5/1/2015 12:01 pm

(Genetic Engineering & Biotechnology News) May 1, 2015 - Telomere length hasn’t been a reliable yardstick for measuring the progress of cancer.

TESARO Announces Completion of Targeted Enrollment in Phase 3 NOVA Trial and Initiation of the QUADRA Trial of Niraparib

5/1/2015 12:01 pm

(CNNMoney) Apr 30, 2015 - TESARO, Inc., an oncology-focused biopharmaceutical company, today provided an update on its niraparib clinical development program.

Higher CVD Risks Reported for Hodgkin's Lymphoma Survivors

4/28/2015 12:00 pm

(Medscape Medical News) Apr 27, 2015 - Hodgkin's lymphoma (HL) is a curable disease with 10-year survival rates of greater than 80%. However, patients reaching adulthood show an increased incidence of cardiovascular disease (CVD) as a result of the therapy they received, and they are likely to turn to primary care physicians for treatment.

Angry Over Drug Prices, More States Push Bills for Pharma to Disclose Costs

4/24/2015 11:04 am

(Wall Street Journal/Pharmalot blog) Apr 24, 2015 - Should drug makers be required to disclose their costs to justify rising prices?

New Blood Test Shows Promise in Cancer Fight

4/20/2015 06:04 am

(New York Times) Apr 19, 2015 - In the usual cancer biopsy, a surgeon cuts out a piece of the patient’s tumor, but researchers in labs across the country are now testing a potentially transformative innovation.

NCCN Holds Fourth Annual State Oncology Society Forum

3/31/2015 12:01 pm

(NCCN) Mar 31, 2015 - The fourth annual state oncology society forum, held in conjunction with NCCN’s 20th Annual Conference, examined accountable care, payment reform, and best practices from community oncologists.

Obama Says He's Ready to Sign Fix of Medicare Doctor Payments, Without Endorsing Legislation

3/25/2015 12:04 pm

(U.S. News & World Report/Associated Press) Mar 25, 2015 - President Barack Obama said Wednesday that he's ready to sign good bipartisan legislation to fix Medicare's doctor payment problem, without endorsing any specific legislation.

Dietary Dioxins Don't Seem to Increase Breast Cancer Risk: Study

3/18/2015 11:04 am

(Drugs.com/HealthDay News) Mar 17, 2015 - Consuming low levels of chemicals called dioxins in food doesn't increase the risk of breast cancer, contends a new study that challenges a widely held belief about the effect of dioxins.

Study: Prices of Cancer Drugs Have Soared Since 1995

3/18/2015 11:04 am

(MIT News) Mar 18, 2015 - The prices of leading cancer drugs have risen at rates far outstripping inflation over the last two decades, according to a new study co-authored by an MIT economist — but the exact reasons for the cost increases are unclear.

Exact Sciences' Cologuard Gets Aetna Medicare Advantage Coverage

3/4/2015 12:03 pm

(GenomeWeb) Mar 4, 2015 - Exact Sciences today announced that Aetna will cover its Cologuard test under its Medicare Advantage plan, which serves 967,000 members across the country.